In the dynamic world of biologics manufacturing, change remains one of the few constants. As new modalities and innovations continuously emerge, the future holds promising prospects for patients. However, manufacturers face the challenge of keeping pace with these advancements and determining the best areas for investment. Amidst these changes, another significant trend is gaining serious momentum: sustainability.
According to our 2024 Global Biopharma Sustainability Review survey, which gathered insights from 800 pharma and biopharma executives, an impressive 62% indicated that sustainability will be the top priority for their companies over the next five years. This shift towards sustainability reflects a broader commitment to environmental stewardship, ethical practices, and long-term viability. Manufacturers are increasingly recognizing the importance of integrating sustainable practices into their operations. By prioritizing sustainability, companies are not only contributing to a healthier planet but also enhancing their reputation and meeting the growing expectations of stakeholders and consumers.
Access the full article to learn more.